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Summary The 17th International Leprosy Congress (ILC), organised by the
International Leprosy Association, took place in Hyderabad, India from 30th January
to 4th February 2008. The venue for the congress was the Hyderabad International
Convention Centre.
The presentations that were of particular interest are mentioned here.
Introduction
The Hyderabad International Convention Centre (HICC) opened 2 years ago and provided
excellent facilities for more than 1500 ILC delegates, representing more than 50 countries,
who attended the 17th ILC.
Delegates received a substantial conference pack including a multilingual CD ROM of
ILEP Technical Publications. A free copy of the December 2007 issue of Leprosy Review
was also available from the LEPRA stand. Appropriately the cover photograph of this issue
shows children at a LEPRA jeep in Hyderabad.
The catering at the congress was superb and the HICC has many comfortable breakout
zones where acquaintances were made and renewed, discussions provoked by presentations
were continued or where delegates were able simply to relax. The wonderful environment of
the conference venue was more than matched by the enthusiasm of the delegates and more
than one person commented on the vibrant nature of the congress. The delegates and congress
organisers are to be congratulated for such a wonderful atmosphere. There was a very
enjoyable Gala Dinner at the Rocks Park with entertainment provided by a dance troupe (and
also by some of the delegates).
The interests and disciplines represented at the congress were remarkably broad.
The common goal of reducing the burden of the disease is sought by a diverse constituency
including leprosy-affected individuals involved in political activism, non-governmental
organisations, the pharmaceutical multi-national Novartis, the World Health Organization
and national governments. The support of the Indian government was a major factor in
making the congress such a success.
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Research was presented from a wide range of disciplines – from molecular biology to
social anthropology – reflecting the challenges leprosy still poses.
Papers were presented during more than 150 hours of pre-congress workshops, plenary
and free paper sessions. Training sessions on topics as diverse as diagnostics and legal issues
were also available to delegates.
The congress was eagerly awaited coming, as it did, in the wake of the Indian government
announcing in January 2006 that India had reached the elimination target of less than one case
per 10,000 population.
The integration of leprosy services into general health care systems is a challenge in
maintaining expertise and interest in the disease. The congress inauguration was attended by
the Governor of Andhra Pradesh, N.D. Tiwari, who stressed the need for all those involved in
combating leprosy to remain vigilant and avoid complacency.
A team of Leprosy Review/London School of Hygiene & Tropical Medicine volunteers
attended as many sessions as possible and sought the opinions of other delegates in order to
report the presentations of particular interest. Many of the presentations from the plenary
sessions are available to view or download from Associazione Italiana Amici di Raoul
Follereau (AIFO) website: http://www.aifo.it/english/resources/online/books/leprosy/
ila-india08/index.htm
M. LEPRAE GENOME
Stewart Cole gave an invited lecture on the developments in the understanding of the M.
leprae genome.1 The abundance of pseudogenes compared to functional counterparts within
the genome of M. tuberculosis helps explain the intracellular nature of M. leprae and its
inability to grow in axenic media. The sequence of a Brazilian isolate of M. leprae is almost
identical to that of the Indian strain originally sequenced. They differed by 118 single
nucleotide polymorphisms. Other studies suggest that leprosy is due to single clone. The
phylogeographical hypothesis is that the organism originated in eastern Africa and arrived in
other regions following human migrations.
Diana Williams presented data showing that a large number of pseudogenes are
transcribed but remain phenotypically silent.2
GENETIC SUSCEPTIBILITY
The large study of the isolated and genetically homogeneous Prato community in the state of
Para`, Brazil is underway and was described by Marcelo Mira. Combining the detailed
pedigree information obtained, with data from genetic studies may yield further insights into
host susceptibility to M. leprae.3
IMMUNOLOGY, MOLECULAR BIOLOGY AND DIAGNOSTICS
Sergio Antunes presented work showing that in vitro stimulation of Schwann cells with M.
leprae induces matrix metalloproteinase (MMP)-9. The protein staining of MMP-2 and 9 and
the MMP inhibitor TIMP-1 varies depending on the presence of inflammation and fibrosis.4
The plasma levels of the chemokine IP-10 (CXCL10) were increased in Brazilian patients
experiencing type 1 reactions compared to matched controls.5 The use of this as a potential
marker of type 1 reaction is being investigated.
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Luna Azulay-Abulafia described seven cases of Lucio’s phenomenon all of whom had
anti-cardiolipin antibodies and responded to treatment with multi-drug therapy (MDT)
alone.6 She discussed the similarities between Lucio’s phenomenon and the anti-
phospholipid syndrome.
ANIMAL MODELS
The renewed interest in the nine banded-armadillo (Dasypus novicemtus) as an animal model
following the sequencing of the species’ genome was discussed by Richard Truman.7 The
comparison of the human and armadillo genomes is also underway. The armadillo cytokines
interferon (IFN)-g and tumour necrosis factor-a have been cloned. The armadillo IFN-g
similar to its human counterpart did not induce the killing of intracellular mycobacteria.8
LEPROSY AND HIV
A plenary session was devoted to M. leprae and HIV co-infection. Annemieke Geluk
suggested that site specific differences in T cell responses (between lung and nerve) may help
explain the different impacts of M. tuberculosis and M. leprae on HIV infected individuals.9
The clinical experience of leprologists from Brazil, Ethiopia and India of managing leprosy in
HIV infected individuals was presented. Case series of leprosy type 1 reactions presenting as
immune reconstitution disease (IRD) after the initiation of anti-retroviral therapy were
presented. The first report of erythema nodosum leprosum (ENL) presenting as IRD, in a
woman with lepromatous leprosy from the Dominican Republic, was presented by Juan
Periche Fernandez.10
REACTIONS AND NERVE DAMAGE
The results of nerve function assessments of the INFIR cohort study were presented in several
papers. Wim van Brakel and Peter Nicholls demonstrated that changes in sophisticated nerve
assessment tools particularly sensory nerve conduction amplitudes occur well before changes
in monofilament and voluntary motor testing occur.11,12 The changes are also predictive of
new events of nerve function impairment.13
Fatema Khambati presented a study of a cohort from Mumbai and found that changes in
nerve conduction studies were useful in detecting nerve function impairment.14
The use of thalidomide in the management of ENL was reported in several large
uncontrolled case series. The number of patients included in these presentations and the
different ways in which thalidomide was used support the need for well designed randomised
controlled clinical trials, which will provide better evidence for the role of thalidomide in the
management of ENL.
Maria Balagon presented a controlled study of the incidence of ENL in two non-
randomised groups (recruited at different times) of patients receiving 12 and 24 months of
multibacillary (MB) MDT.15 The group treated for 12 months were almost twice as likely to
have ENL. This group was far more likely to have more severe ENL. They attribute this to the
loss of the protective effect of clofazimine.
Policy makers will need to be cognisant of such data particularly with respect to uniform
MDT in which all patients (both paucibacillary and MB) will be treated with just 6 months of
rifampicin, dapsone and clofazimine.
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PAIN
Patrick Stump presented a study of 50 patients who complained of pain during leprosy
reactions.16 Pain was common and often chronic. There was a negative impact on quality of
life measurements.
The use of carbamazepine to treat neuropathic pain was presented by Dr Pai. Twelve of
the 14 patients reported improvement in their symptoms. The discussion provoked by the
paper supported the view that neuropathic pain is under reported and that the evidence on
which to base effective treatment is lacking.17
MULTI -DRUG THERAPY AND DRUG RESISTANCE
The assessment of uniform MDT (6 months rifampicin, dapsone and clofazimine) is
underway but as yet there is no data regarding relapse rates. Patients with MB disease treated
with a 6 months MDT regime did not have as much improvement in clinical and histological
parameters as those treated for 12 months.18
The use of molecular tools for monitoring drug resistance is feasible and simplification of
techniques may allow such tools to be used in field laboratory settings.19
EPIDEMIOLOGY
Paul Fine highlighted the difficulties in comparing data from different periods due to the
frequent changes in case definitions and the different statistics used to record the burden of
disease.20 Dr Krishnamurthi discussed the thorny issue of case detection rates and how
heavily influenced this statistic is by operational factors.21
Data from a collaborative study of the molecular epidemiology of M. leprae isolates from
a hyperendemic county in China were presented by Varalakshmi Vissa.22 Cases within
families share similar patterns of variable number tandem repeats in the M. leprae DNA
isolated from them. The method used multiple-locus variable-number tandem-repeat analysis
which provides a means for tracking the transmission of M. leprae.
Preliminary results from Venezuela of increased rates of SNP-type-4 in skin biopsies
from cases in hyperendemic regions compared with those taken from individuals from non-
hyperendemic (,1 case/10 000 population) regions may have interesting implications for
pathogenesis.23
PREVENTION OF DISABILITY (POD)
Hugh Cross emphasised the need for early detection and treatment of leprosy to prevent
neuropathy and the risk of disability.24 There is a need to improve on the limited evidence
supporting the use of self-care and footwear interventions in POD. The framework in which
POD interventions are provided needs to shift to a model in which affected persons determine
the impact of their condition and are supported by health workers.
Abhijit Joshi outlined a cascade model for the training of trainers in self-care and POD,
who then go on to train others. This resulted in rapid dissemination of knowledge.25
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COMMUNITY-BASED REHABILITATION
Mary Amylike described how community-based rehabilitation projects such as soap making
cooperatives in Nigeria have helped many leprosy-affected people. The Common Vocational
training Project in Pune, India has links with major corporations.26 Neela Shah reported that
small business loans for income generating schemes continue to be a success.27
HUMAN RIGHTS, SOCIAL ASPECTS AND EMPOWERMENT
Yo¯hei Sasakawa, the WHO Goodwill Ambassador for the Elimination of Leprosy, stated that
society still marginalises leprosy-affected people in denial of their human rights.28 Doug
Soutar emphasised that human rights should not be seen as relating only to health and
disability.29 Natalie Marcal from IDEA Angola described how Women’s groups had
facilitated empowerment of marginalised leprosy-affected women.
HEALTH AND HEALTH PROMOTION
Faustino Francisco described how the Telehansen project run by Morhan in Brazil provides
an information and advice line with a toll free number. The aim of provision of free access to
such information is to promote knowledge of leprosy, aid elimination and reduce stigma.
Conclusions
The ILC provides a unique forum for the leprosy community to share ideas and develop
common goals.
Reducing the burden of leprosy requires continued high quality research to understand:
the organism, its interaction with the host, the disease, treatments and how best to institute
them, the prevention of disability and how stigma can be eradicated and the human rights of
individuals ensured. The adequate funding of such research is essential and this is something
that will require sustained advocacy from all stakeholders throughout the next 5 years.
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